Stock 2257 SIRNAOMICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:25 30/05/2024 BST 		5-day change 1st Jan Change
7.48 HKD +0.27% Intraday chart for Sirnaomics Ltd. -8.45% -79.11%
05-20 Sirnaomics' Strategy Chief Steps Down MT
05-17 Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sirnaomics' Strategy Chief Steps Down
MT
Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer
CI
Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director
CI
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment
MT
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ
CI
Sirnaomics Announces 2023 Annual Results
PR
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
PR
Sirnaomics Chairman Disposes of Shares
MT
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024
PR
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors
PR
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770
PR
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug
MT
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study
MT
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
PR
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
CI
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
AQ
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
PR
Sirnaomics Ltd. Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2257 Stock
  4. News Sirnaomics Ltd.